Operator Ladies and gentlemen, thank you for standing by, and welcome to the fourth-quarter 2020 Geron earnings conference call. [Operator instructions] I would now like to hand the conference over to Olivia Bloom, Geron's chief financial officer. Thank you. Please go ahead, ma'am. Olivia Bloom -- Chief Financial Officer Thank you, Erica, and good afternoon, everyone. Thank you for joining us for today's conference call. I'm joined today by Dr. John Scarlett, Geron's chairman and chief executive officer; and Aleksandra Rizo, our chief medical officer. After the market close today, we announced our fourth quarter and year-end 2020 financial results and operational highlights via press release, which is available on our website under geron.com/investors. In addition, a live webcast of this call is available on our website, and an archive will be available for 30 days. Before we begin, please note that this presentation and question-and-answer session will contain forward-looking statements relating to Geron's plans, expectations, timelines, beliefs, statements of potentiality and projections. These include, without limitation, those regarding the expected time lines for completion of enrollment and the results from the IMerge phase three and IMpactMF clinical trials and submission of an NDA, the potential for positive outcomes from IMerge phase three and IMpactMF, potential approval imetelstat by regulatory authorities and commercialization of imetelstat, the expectation that Geron's current financial resources will be sufficient to fund its operations until the end of 2022, and that imetelstat has the potential to be disease-modifying and alter the course of MDS and MF.